Clinical Trial

Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee

Study acronym: Endo2/SA3
Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis. Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Enrolling by Invitation 2026-07-28
notable Primary completion pushed: 2025-12-31 -> 2026-12-31 2026-07-28
Trial Details
NCT Number NCT05059626
Lead Sponsor Penn State University
Collaborators: The John B. Pierce Laboratory
Conditions Endometriosis
Enrollment 28 participants
Start Date 2023-12-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-27